Some Asian Shares Buoyed By News On Coronavirus Vaccine
Asian shares were mixed Tuesday, after the Dow Jones Industrial Average hit a record high on optimism that a vaccine may soon control the coronavirus and the economic destruction its caused.
- Associated Press
- Last Updated: November 17, 2020, 20:48 IST
- FOLLOW US ON:
NEW YORK: U.S. stocks are falling in early trading on Tuesday, giving back a bit of the big gains made this month that vaulted them back to record heights.
Treasury yields also sank after a report showed U.S. shoppers spent less at retailers last month than economists expected. The numbers underscore how the coronavirus pandemic is continuing to worsen and threatening to drag the economy lower, at least in the near term.
Stocks that stormed higher this month on hopes that a vaccine or two may get the global economy back to normal next year receded amid the worries, particularly airlines, energy producers and other companies that would benefit most from a reopening economy.
The S&P 500 was down 0.9% in early trading, on pace for its first drop in three days. The Dow Jones Industrial Average was also pulling lower from its record high, and it was down 369 points, or 1.2%, at 29,581, as of 9:52 a.m. Eastern time. The Nasdaq composite was 0.5% lower.
Sharp losses for companies in the pharmacy business helped drag the market lower after Amazon targeted them as the latest industry its trying to upend. The retailing behemoth opened an online pharmacy Tuesday that allows customers to have prescriptions delivered to their door in a couple days.
CVS Health fell 7.6%, Walgreens Boots Alliance dropped 7.9% and Rite-Aid lost 12.9%. Amazon, meanwhile, rose 1.1%.
On the winning side was Tesla, which soared 12.1% following an announcement that it will join the S&P 500 index next month. The index is hugely influential, and nearly $4.6 trillion at the end of last year was in funds that mimic the S&P 500.
The electric-vehicle company had already soared 388.8% in 2020 before Monday evenings index announcement. Its grown so massive that the company behind the S&P 500 is asking investors whether they think it should add Tesla to the index all at once or in two steps.
The broader stock market was slowing Tuesday, though, and 89% of stocks in the S&P 500 were lower.
Sales at U.S. retailers rose 0.3% last month from September, a sharp slowdown from Septembers 1.6% growth. The figure also fell short of economists expectations for 0.5% growth.Part of the shortfall is likely because laid-off workers are no longer getting extra unemployment benefits from the U.S. government following the expiration of several financial-support programs from Congress. Democrats and Republicans in Washington have talked about the possibility of renewing some of the programs, but progress has been painfully slow amid deep partisanship in Washington.
Thats layering on top of the already accelerating pandemic, which is pushing governments across the United States and Europe to bring back varying degrees of restrictions on daily life in hopes of slowing the spread of the virus. Health experts are warning of a bleak winter on the way.
Thats all helped dilute some of the optimism thats rushed through markets since early last week. Companies have released encouraging early results for a couple potential COVID-19 vaccines, which is raising hopes that the economy can get back to normal and stocks beaten down during the pandemic can roar back to life. Even with Tuesdays decline, the S&P 500 is still up 10% for November so far. Thats better than any monthly performance for the index since April, when stocks were exploding higher following their pandemic-induced plunge.
The yield on the 10-year Treasury fell to 0.86% from 0.89% late Monday.
In Europe, Germanys DAX lost 0.4%, and Frances CAC 40 slipped 0.3%. The FTSE 100 in London fell 1.5%.
In Asia, stocks were mixed. Japans Nikkei 225 rose 0.4%, and Hong Kongs Hang Seng inched up 0.1%. South Koreas Kospi slipped 0.2%, and stocks in Shanghai lost 0.2%.
AP Business Writer Yuri Kageyama contributed.
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor